Company
Melbourne, VIC
Every investor coverage indicates participated in a round Cerulea Clinical Trials raised.
Companies Cerulea Clinical Trials acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Stéphane Chatonsky | Non-executive Director | @AuManufacturing |
Stories naming Cerulea Clinical Trials. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Breakthrough Victoria rounds up April–May 2026 portfolio news, including grants for Number 8 Bio and Xefco, Liquid Instruments' Series C, program selections, partnerships, regulatory clearances and two new Aravax directors.
Breakthrough Victoria marks the opening of an eye research facility it backed with $10 million; the CERA-affiliated centre expects to treat thousands of patients and create dozens of jobs.